Gfb-887 ic50
WebNov 8, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today provided an update on TRACTION-2, its ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental … WebJul 14, 2024 · The GFB (Fig. 1) was first described more than 50 years ago, and is a unique structure comprising highly fenestrated and specialized endothelial cells, an unusual …
Gfb-887 ic50
Did you know?
WebJul 23, 2024 · GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular … WebJun 25, 2024 · An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases. November 10, 2024 updated by: Goldfinch Bio, Inc. This is an open …
WebGFB-887 is a sub-type selective, small molecule TRPC5 ion channel inhibitor that has been shown in preclinical models to prevent podocyte damage mediated by Rac1 activation. … WebJun 23, 2024 · Goldfinch Bio’s TRACTION-2 clinical research trial is evaluating an investigational precision medicine, GFB-887, for the potential treatment of TRMCD and FSGS. The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to kidney diseases caused by podocyte injury.
WebJul 1, 2024 · GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular … WebFeb 2, 2024 · Researchers have suggested that targeting brain TRPs could be a useful approach to developing therapeutics for psychiatric and neurogenerative disorders. GFB-887 was developed by Goldfinch to treat patients with kidney disease. The company announced positive results from the Phase II trial in February 2024.
WebFeb 28, 2024 · Goldfinch Bio today announced positive preliminary data from its ongoing Phase 2 clinical trial evaluating GFB-887, a podocyte-targeting small molecule inhibitor …
WebMay 13, 2024 · A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 … line up and wait faaWebJun 30, 2024 · Goldfinch is currently advancing two programs through development: GFB-887, a first-in-class selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5) and GFB-024, a... hot tub cabin rentals west virginiaWebJul 27, 2024 · End Date: September 01, 2025. Summary: This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal … line up and sound off vancouver waWebJun 1, 2024 · FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects. Official Title: A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects. Secondary IDs: 8391348 [Covance] Study Status. line up and down copy pasteline up and taperWebOct 1, 2024 · GFB-887 is a podocyte-targeting, small molecule TRPC5 inhibitor designed specifically to treat patients with kidney diseases characterized by an overactivation of … line up and wait atcWebJun 25, 2024 · This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD) Study Overview Status Terminated Conditions Kidney Diseases Glomerulonephritis Nephritis Nephrosis Glomerulosclerosis hot tub cabins for rent